Description: Resonance Health Limited is principally engaged in the development and commercialization of technologies and services for the quantitative analysis of radiological images. The Company's segments include Services, Research and Development, and Corporate. The Company's core product is FerriScan, which is a non-invasive liver diagnostic technology used for the measurement of iron in the liver. FerriScan is used for liver iron concentration (LIC) measurement from magnetic resonance imaging (MRI) scans of a patient's liver. The FerriScan analysis procedure produces a mean LIC measurement and a color coded map reflecting the iron distribution across the liver. The Company's product HepaFat-Scan, is a non-invasive method for measuring volumetric liver fat fraction (VLFF) from MRI scans. HepaFat-Scan is provided as an image analysis service. HepaFat-Scan is available for routine clinical use and for use in pharmaceutical company clinical trials.
Home Page: www.resonancehealth.com
RHT Technical Analysis
141 Burswood Road
Burswood,
WA
6100
Australia
Phone:
61 8 9286 5300
Officers
| Name | Title |
|---|---|
| Mr. Mitchell M. Wells B.Com., B.Comm, L.L.B., LLB | MD, Joint Company Sec. & Exec. Director |
| Mr. Nicholas Allan A.C.A., B.Com. | CFO, COO & Joint Company Sec. |
| Mr. Ben Winters | Chief Technology Officer |
| Ms. Liesl Ellies | Gen. Counsel & Joint Company Sec. |
| Mr. Chad Tondut | Communications Mang. and GM of Products & Portfolio |
| Mr. Ajay Nair | Gen. Mang. of Global Sales & Marketing |
| Dr. John Olynyk BMedSc, FRACP, M.D., MBBS | Chief Medical Officer |
| Dr. Timothy Guy St. Pierre B.Sc(Hons), Ph.D. | Chief Research Scientist |
| Dr. Wenjie Pang Ph.D. | Chief Scientific Officer ? Imaging & AI |
| Dr. Sherif Boulos Ph.D. | Chief Scientific Officer of Molecular |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Equipment |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.1135 |
| Price-to-Sales TTM: | 6.3344 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |